-
[show abstract]
[hide abstract]
ABSTRACT: OBJECTIVE: Ga-NOTA-RGD PET is a newly developed molecular imaging for angiogenesis. In this study, Ga-NOTA-RGD PET was used to investigate imaging characteristics in a rat myocardial infarction (MI) model and to monitor the efficacy of an angiogenesis induction therapy. MATERIALS AND METHODS: Ga-NOTA-RGD PET was performed serially in rats with MI or sham operation, and myocardial uptake was analyzed with respect to time duration and tissue characteristics. Subsequently, Ga-NOTA-RGD PET was serially performed for therapeutic efficacy monitoring in MI-induced rats, which were treated with basic fibroblast growth factor (bFGF) injection or saline injection. Image findings were compared with the final change in MI lesion. RESULTS: Ga-NOTA-RGD uptake was significantly increased in MI lesion and gradually decreased over time. Ga-NOTA-RGD uptake in the infarcted tissue corresponded with vascular endothelial growth factor expression and macrophage accumulation. In monitoring of therapeutic efficacy, the lesion uptake in the bFGF-injected group was significantly higher than that of the saline-injected and sham-operated groups on the first day. However, no significant differences were observed between bFGF and saline-injected groups at subsequent time points, corresponding to the final infarct size change. CONCLUSION: Ga-NOTA-RGD PET would be a useful angiogenesis imaging modality in MI for assessment of pathophysiology or monitoring of therapeutic efficacy.
Coronary artery disease 03/2013; · 1.56 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: Castleman disease (CD) is a benign lymphoproliferative disease, which usually shows hypermetabolism on F-FDG PET/CT. In this study, we investigated metabolic characteristics of CD in consecutive series of patients and analyzed F-FDG uptake with regard to major clinicopathologic factors, to investigate clinical implication of F-FDG uptake in CD. METHODS: Twelve patients (5 men and 7 women; mean age, 52 ± 14 years) with pathologically confirmed CD, who underwent F-FDG PET/CT, were retrospectively enrolled, and their images were analyzed. The cases were composed of 10 first diagnosed and 2 relapsed cases. SUVmax was measured for each lesion. Metabolic characteristics were compared according to clinical and pathologic characteristics. RESULTS: All the F-FDG PET/CT images showed hypermetabolic lesions including small lymph nodes of less than 1 cm. The average SUVmax was 5.8 ± 4.1 with a varying range of 2.4 to 17.1. SUVmax was significantly higher in multicentric than in unicentric disease cases (7.0 ± 4.6 vs 3.3 ± 1.1; P = 0.048) and in the patients with clinical manifestation than the other group (7.1 ± 4.5 and 3.1 ± 0.8, respectively; P = 0.028). CONCLUSIONS: F-FDG PET/CT is an effective diagnostic imaging for diagnosis of CD. Castleman disease shows moderately increased F-FDG uptake. In addition, the uptake is well correlated with disease multicentricity and clinical manifestation, suggesting that it would be a significant imaging marker for severity or prognosis of CD.
Clinical nuclear medicine 02/2013; · 3.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: INTRODUCTION: ALK rearrangement in lung cancer has been identified as a novel molecular target in lung adenocarcinoma. In this study, we evaluated metabolic and metastatic features of lung adenocarcinoma by using FDG PET/CT, with regard to specific genotypes of ALK and EGFR mutation. METHODS: Patients with lung adenocarcinoma initially diagnosed and examined with FDG PET/CT and molecular genotyping with biopsy specimen, from September 2009 to September 2011, were selected retrospectively. ALK fluorescence in situ hybridization and EGFR mutations were tested. Maximum standardized uptake value (SUVmax) and metastatic characteristics on FDG PET/CT were analyzed with regard to ALK and EGFR status. RESULTS: Of the 331 lung adenocarcinoma patients, 18 were ALK positive (ALK(+)), 156 were EGFR mutation positive (EGFR(+)), and 157 were wild type (WT) for both ALK and EGFR mutation. The ALK(+) tumor showed significantly higher SUVmax and more common metastasis to lymph nodes and distant organs than those of other genotypes in overall patients (P<0.01). In a subgroup analysis of advanced stage (stage IIIb and IV), ALK(+) lung cancer showed significantly higher SUVmax (P<0.05) than EGFR(+) tumors. In another subgroup analysis of size matched groups, ALK(+) tumors showed significant difference in SUVmax, lymph node and distant metastasis (P<0.01), particularly in the moderate-sized tumors (1.5-3cm). CONCLUSION: ALK-rearranged lung adenocarcinoma represents higher glucose metabolism and more rapid metastasis to lymph nodes or distant sites compared with those with EGFR mutation and wild type, which suggests more aggressive features of ALK rearrangement.
Lung cancer (Amsterdam, Netherlands) 12/2012; · 3.14 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Indocyanine green (ICG) is an FDA-approved near infrared (NIR) fluorescent dye used in clinical imaging. However, its applications remain limited due to its short half-life, nonspecific plasma binding, optical instability, and poor aqueous stability. Dye doped silica nanoparticles provide an effective barrier in keeping the dye away from the surrounding environment, but ICG cannot be encapsulated into silica easily by conventional methods. In this study, ICG molecules ion-paired with a cationic polymer polyethylenimine (PEI) were successfully encapsulated into a silica matrix to form ICG doped silica nanoparticles by using the Stöber method. Pairing with PEI reduced self-quenching of fluorescence by preventing the aggregation of ICG molecules in silica nanoparticles. Dye leakage was also reduced to the level of 3-6% loss in 5 days. NIR fluorescence images of ICG doped silica NPs below a 2.0cm thick porcine muscle sample illuminated by NIR light were obtained.
Talanta 09/2012; 99:387-93. · 3.79 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the efficacy of post-treatment positron emission tomography (PET)/computed tomography (CT) for identification of tumor recurrence, and to determine whether [(18)F]fluorodeoxyglucose (FDG) uptake measured as the maximum standardized uptake value (SUV(max)) has predictive role regarding survival in patients with uterine cervical cancer.
Medical records from 276 women with uterine cervical cancer who had post-treatment [(18)F]FDG PET/CT performed were retrospectively reviewed. Results of PET/CT scans were compared with histological or clinical examination.
Ninety-five (34.4%) of the 276 patients had documented recurrence by either surgical biopsy or clinical and imaging follow-up. Median duration from treatment to PET/CT scan was 24 months (range, 6-307). The overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of post-treatment PET/CT were 94.7%, 87.8%, 80.4%, 97%, and 90.2%, respectively. The PET/CT scan modified both the diagnostic or treatment plan in 67 patients (24.3%). Patients were divided into two groups according to cut-off SUV(max) established on the basis of ROC analysis (<5.25 vs. ≥5.25), and there was a significant difference in OS between groups (p=0.001). In addition, the 5-year progression-free survival (PFS) and OS rates of patients with a negative PET/CT scan for recurrence were significantly better than those with a positive PET/CT (98.62% vs. 17.83%, p<0.0001 for PFS, 99.31% vs. 85.38%, p=0.0015 for OS).
Post-treatment PET/CT scan is a sensitive and accurate surveillance modality, and provides prognostic information in uterine cervical cancer. Furthermore, it may allow individualization of patient care.
European journal of radiology 05/2012; 81(8):e817-22. · 2.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Paragangliomas are extra-adrenal neuroendocrine tumors that are derived from neural crest cells. Among all the paragangliomas,
those in a pelvic location are extremely rare. In addition, the prevalence of nonfunctioning paragangliomas is underestimated
because of their clinical latency, and they are often underdiagnosed unless they cause symptoms. We report a case of a nonfunctioning
periurethral paraganglioma that was incidentally detected by FDG PET/CT during regular follow-up after excision of a melanoma
on the left thumb.
KeywordsNonfunctioning periurethral paraganglioma–Extra-adrenal pheochromocytoma–FDG PET/CT
04/2012; 45(2):145-148.
-
[show abstract]
[hide abstract]
ABSTRACT: The expression of glucose transporters (Glut-1, Glut-3), hexokinase-II, and Ki-67 has been proposed to explain intratumoral
heterogeneous F-18 fluorodeoxyglucose (FDG) uptake. We report a case of Krukenberg tumor with intratumoral heterogeneous FDG
uptake which corresponded well with the expression levels of Glut-1 and ki-67. Fused positron emission tomography (PET)/magnetic
resonance (MR) imaging was helpful for localizing the metabolically active area in the tumor specimen. This report elucidates
the relationship between the intratumoral heterogeneous FDG uptake and biologic heterogeneity, and shows the usefulness of
PET/MR in research on intratumoral heterogeneity.
KeywordsFDG–PET/CT–PET/MRI–Glut-1–Ki-67–Krukenberg tumor
04/2012; 45(2):139-144.
-
[show abstract]
[hide abstract]
ABSTRACT: PurposeWith the recent increase in incidence of thyroid cancer, non-hospitalized low-dose (NH-LD) radioiodine treatment (RIT) has
also increased rapidly. The radioactivity limit that is allowed to be administered without hospitalization depends on individual
calculation, based partly on patients’ behavior. In this study, Korean patients’ behavior in relation to radiation safety
in NHLD RIT was surveyed.
MethodsA total of 218 patients who underwent NH-LD RIT of 1.1GBq 131I in a single center were surveyed. The patients underwent RIT with a standard protocol and the survey was performed by interview
when they visited subsequently for a whole-body scan. The survey questionnaire included three parts of questions: general
information, behavior relating to isolation during RIT, and awareness of radiation safety.
ResultsAfter administration of radioiodine, 40% of patients who returned home used mass transportation, and another 47% went home
by taxi or in car driven by another person. Isolation at home was generally sufficient. However, 7% of patients did not stay
in a separate room. Among the 218 patients, 34% did not go home and chose self-isolation away from home, mostly due to concerns
about radiation safety of family members. However, the places were mostly public places, including hotels, resorts, and hospitals.
About half of the patients replied that access to radiation safety information was not easy and their awareness of radiation
safety was not satisfactory. As a result, 45% of patients wanted hospitalized RIT.
ConclusionsIn many countries, including Korea, RIT is continuously increasing. Considering the radiation safety of patients’ family members
or the public and the convenience of patients, the pretreatment education of patients should be enhanced. In addition, the
hospitalization of patients having low-dose therapy is recommended to be seriously considered and expanded, with the expansion
of dedicated treatment facilities.
KeywordsThyroid cancer-Radioiodine treatment-Behavior-Radiation safety-Hospitalization
04/2012; 44(4):267-272.
-
[show abstract]
[hide abstract]
ABSTRACT: PurposeThe purpose of this study was to investigate the role of 18F-fluorodeoxyglucose (FDG) PET in detecting high-grade meningioma and predicting the recurrence in patients with meningioma
after surgical resection.
MethodsFifty-nine patients (27 men and 32 women) with intracranial meningioma who underwent preoperative FDG PET and subsequent surgical
resection were enrolled. All patients underwent clinical follow-up for tumor recurrence with a mean duration of 34±20months.
The tumor to gray matter ratio (TGR) of FDG uptake was calculated and a receiver-operating characteristic (ROC) curve of the
TGR was drawn to determine the cutoff value of the TGR for detection of high-grade meningioma. Further, univariate analysis
with the log-rank test was performed to assess the predictive factors of meningioma recurrence.
ResultsThe TGR in high-grade meningioma (WHO grade II and III) was significantly higher than that in low-grade ones (WHO grade I)
(p=0.002) and significantly correlated with the MIB-1 labeling index (r=0.338, p=0.009) and mitotic count of the tumor (r=0.284, p=0.03). The ROC analysis revealed that the TGR of 1.0 was the best cutoff value for detecting high-grade meningioma with a
sensitivity of 43%, specificity of 95%, and accuracy of 81%. Of 59 patients, 5 (9%) had a recurrent event. In the log-rank
test, the TGR, MIB-1 labeling index, presence of brain invasion, and WHO grade were significantly associated with tumor recurrence.
The cumulative recurrence-free survival rate of patients with a TGR of 1.0 or less was significantly higher than that of patients
with a TGR of more than 1.0 (p=0.0003)
ConclusionFDG uptake in meningioma was the significant predictive factor of tumor recurrence and significantly correlated with the proliferative
potential of the tumor.
European journal of nuclear medicine and molecular imaging 04/2012; 36(10):1574-1582. · 4.99 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: ObjectiveThis study was performed to evaluate the clinical value of 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) for cancer screening in Korean asymptomatic
people.
MethodsBetween February 2004 and December 2006, 1,587 asymptomatic individuals underwent FDG PET/CT as part of a cancer screening
program with some other diagnostic tests at the healthcare center of our hospital. After excluding patients with a history
of malignant tumor, 1,336 subjects were enrolled. All PET/CT images were visually analyzed. In subjects showing positive findings
for PET/CT or other screening tests, further diagnostic tests and pathological confirmation were performed.
ResultsOf the 1,336 subjects, malignant tumors were found in 16 participants (1.2%, thyroid cancer: 9, lung cancer: 2, stomach cancer:
2, and others: 4). There were 47 cases (3.6%) of positive PET/CT findings—11 cases were true positive (thyroid cancer: 8,
lung cancer: 1, renal cancer: 1, and invasive thymoma), and 36 false positive, and five cases were false negative. The overall
detection rate of PET/CT was 0.8%, and the sensitivity, specificity, positive-predictive value, and negative-predictive value
of PET/CT were 68.8, 97.2, 23.4, and 99.6%, respectively.
ConclusionsFluorodeoxyglucose positron-emission tomography has the potential to detect various kinds of malignant tumors in cancer screening
test, and the overall detection rate of PET/CT was 0.8%. FDG PET/CT can be a useful cancer screening modality with the selection
of high-risk group and appropriate combination with other screening modalities.
Annals of Nuclear Medicine 04/2012; 23(7):685-691. · 1.50 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: PurposeMeasurement of serum hepatitis B virus surface antigen (HBsAg) levels is important for the management of chronic hepatitis
B patients in terms of monitoring response to antiviral therapy. This study aimed to evaluate the diagnostic performance of
a new diagnostic kit, which quantitatively measures serum HBsAg level using an immunoradiometric assay (IRMA)-based method.
Measurements were compared with those obtained using a chemiluminescent microparticle immunoassay (CMIA)-based method.
MethodsThe blood samples of 96 patients with chronic hepatitis B were used in this study. Copy numbers of serum hepatitis B virus
(HBV) DNA were determined in 23 of these samples. The correlation between and the concordance of IRMA and CMIA results were
determined using Pearson’s correlation coefficients. P values of 0.05 were considered to be statistically significant throughout.
ResultsLaboratory diagnoses based on IRMA were wholly in agreement with those based on CMIA. Furthermore, serum HBsAg levels by IRMA
were found to be highly correlated with those determined by CMIA (correlation coefficient R
2 = 0.838, p < 0.001). Serum HBsAg level and serum HBV DNA copies were found to be linearly related by both methods (R
2 = 0.067, p = 0.316 by IRMA, and R
2 = 0.101, p = 0.215 by CMIA).
ConclusionThe diagnostic performance of the investigated IRMA method of determining HBsAg levels was found to be comparable with that
of a CMIA-based method in chronic hepatitis B patients.
KeywordsHepatitis B virus surface antigen–Immunoradiometric assay–Chronic hepatitis B–Chemiluminescent microparticle immunoassay
04/2012; 45(1):15-20.
-
[show abstract]
[hide abstract]
ABSTRACT: Since the specific accumulation of iodide in thyroid was found in 1915, radioiodine has been widely applied to diagnose and
treat thyroid cancer. Iodide uptake occurs across the membrane of the thyroid follicular cells and cancer cells through an
active transporter process mediated by the sodium iodide symporter (NIS). The NIS coding genes were cloned and identified
from rat and human in 1996. Evaluation of the NIS gene and protein expression is critical in the management of thyroid cancer,
and several approaches have been tried to increase NIS levels. Identification of the NIS gene has provided a means of expanding
its role in the radionuclide gene therapy of nonthyroidal cancers as well as thyroid cancer. In this article, we explain the
relationship between NIS expression and the treatment of thyroid carcinoma with I-131, and we include a review of the results
of our experimental and clinical trials.
KeywordsSodium iodide symporter (NIS)-Thyroid cancer-I-131-Gene therapy
04/2012; 44(1):4-14.
-
Hyun Woo Kwon,
Jin Chul Paeng,
Francis Sahngun Nahm,
Seog Gyun Kim,
Tanzeel Zehra,
So Won Oh,
Hyo Sang Lee, Keon Wook Kang,
June-Key Chung,
Myung Chul Lee,
Dong Soo Lee
[show abstract]
[hide abstract]
ABSTRACT: PurposeAlthough the three-phase bone scan (TBPS) is one of the widely used imaging studies for diagnosing complex regional pain syndrome
type I (CRPS-1), there is some controversy regarding the TPBS image criteria for CRPS-1. In this study, we modified the image
criteria using image pattern and quantitative analysis in the patients diagnosed using the most recent consensus clinical
diagnostic criteria.
Materials and MethodsThe study included 140 patients with suspected CRPS-1 (CRPS-1, n = 79; non-CRPS, n = 61; mean age 39 ± 15 years) who underwent TPBS. The clinical diagnostic criteria for CRPS-1 revised by the Budapest consensus
group were used for confirmative diagnosis. Patients were classified according to flow/pool and delayed uptake (DU) image
patterns, and the time interval between the initiating event and TPBS (TIevent-scan). Quantitative analysis for lesion-to-contralateral ratio (LCR) was performed. Modified TPBS image criteria were created
and evaluated for optimal diagnostic performance.
ResultsBoth increased and decreased periarticular DU were significant image findings for CRPS-1 (CRPS-1 positive-rate = 73% in the
increased DU group, 75% in the decreased DU group). The TIevent-scan did not differ significantly between the different image pattern groups. Quantitative analysis revealed an LCR of 1.43 was
the optimal cutoff value for CRPS-1 and diagnostic performance was significantly improved in the increased DU group (area
under the curve = 0.732). Given the modified image criteria, the sensitivity and specificity of TPBS for diagnosing CRPS-1
were 80% and 72%, respectively.
ConclusionsOptimally modified TPBS image criteria for CRPS-1 were suggested using image pattern and quantitative analysis. With the criteria,
TPBS is an effective imaging study for CRPS-1 even with the most recent consensus clinical diagnostic criteria.
KeywordsComplex regional pain syndrome type I–Diagnosis–Three-phase bone scan–Optimal criteria
04/2012; 45(4):261-267.
-
Bhumsuk Keam,
Seock-Ah Im,
Youngil Koh,
Sae-Won Han,
Do-Youn Oh,
Nariya Cho,
Jee Hyun Kim,
Wonshik Han, Keon Wook Kang,
Woo Kyung Moon,
Tae-You Kim,
In Ae Park,
Dong-Young Noh,
June-Key Chung,
Yung-Jue Bang
[show abstract]
[hide abstract]
ABSTRACT: BACKGROUND: The purpose of this study was to determine the usefulness of sequential FDG PET/CTs for prediction of axillary lymph node (ALN) status after neoadjuvant chemotherapy (NAC). METHODS: Seventy-seven stage II or III breast cancer patients who received 3 cycles of neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this prospective study. FDG PET/CTs were acquired before chemotherapy and after the first cycle of chemotherapy for early metabolic response prediction. RESULTS: Patients with pN0 had significantly lower post-NAC ALN standard uptake value (SUV) than those who were pN+ (1.22 ± 1.46 in pN0 vs. 2.13 ± 1.99 in pN+, P = 0.017). Post-NAC ALN size on CT also differed according to pathologic ALN status (6.3 mm in pN0 vs. 11.1 mm in pN+, P = 0.014). When serial FDG PET/CT and chest CT were used, patients with an SUV > 1.5 and post-NAC ALN size ≥10 mm on CT did not achieve pN0 (specificity 100% and positive predictive value 100%). CONCLUSIONS: The serial FDG PET/CT after NAC could predict the pathologic status of ALN before surgery in stage II/III breast cancer. Our findings suggest that the combined use of serial FDG PET/CTs and chest CT might provide better information regarding ALN before surgery.
Breast Cancer 02/2012; · 1.36 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: BackgroundPulmonary sclerosing hemangioma (PSH) has been reported to show increased FDG uptake and be potential false-positives on 18F-FDG PET/CT examination. However, it is still unclear whether the previously-reported high FDG uptake is a universal characteristic of PSH, and furthermore, there have been no investigations on what kind of radiologic or histologic features may have been related with its FDG uptake values.PurposeTo investigate the 18F-FDG PET/CT features of pulmonary sclerosing hemangiomas (PSHs), and to evaluate the relating factors with their FDG uptake values.Material and MethodsWe identified 10 PSHs in eight patients who had a pathologic diagnosis and available antecedent 18F-FDG PET/CT images. 18F-FDG PET/CT images were investigated both qualitatively and quantitatively, along with their histopathologic features. Correlation between 18F-FDG PET features and radiologic as well as histopathologic features were also evaluated.ResultsMean diameter of the 10 PSHs in our study was 16.9 mm ± 6.26 (range 5-25 mm). Four tumors showed intense uptake, and four tumors showed moderate uptake on 18F-FDG PET/CT scans. In the remaining two tumors, there were no significant FDG uptakes. The SUVmax of tumors ranged from 0.60-4.7 (median 2.30; 2.51 ± 1.42), and was significantly correlated with the tumor size (r = 0.754, P = 0.012) and three out of four tumors ≥2 cm (75%) showed intense FDG uptake and their SUVmax values were greater than 2.5. Immunohistochemical results for GLUT-1, GLUT-4, and Ki-67 and other pathologic features were not correlated with the tumors' FDG uptake.ConclusionThe majority of PSHs show increased FDG uptakes, and their SUVmax values are significantly correlated with their tumor size. PSH ≥2 cm can frequently be falsely interpreted as malignancy in FDG-PET/CT. Further studies with large study population are warranted to confirm our observations.
Acta Radiologica 01/2012; · 1.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Unexpected focal 18F-FDG breast uptakes are occasionally identified on PET/CT due to its increased use for cancer staging and follow-up. The need for their characterization has been suggested.
To retrospectively evaluate the diagnostic value of ultrasonography (US) in distinguishing benign from malignant lesions for unexpected focal 18F-FDG uptakes in breast on PET/CT scans.
Between April 2004 and January 2010, 27 focal 18F-FDG breast uptakes in 27 patients (age range 33-62 years; mean age 46 years) among 5214 patients who had undergone PET/CT scans were retrospectively analyzed. The American College of Radiology (ACR) Breast Imaging-Reporting and Data System (BI-RADS) final assessment categories of the US and the maximum standardized uptake values (SUVs) of the lesions were compared between the benign and malignant lesions.
Of the 27 lesions, 15 (56%) lesions were malignant. The rate of malignancy, according to the final assessment category on the US, was 0% (0 of 6) for category 3, 60% for category 4 (9 of 15), and 100% (6 of 6) for category 5 (P = 0.001). The US evaluation revealed a sensitivity of 100% (15 of 15) and a specificity of 50% (6 of 12). The average maximum SUV of the malignant lesions was greater than that of the benign lesions (4.12 ± 1.94 vs. 1.94 ± 0.82; P = 0.001).
US evaluation of unexpected focal 18F-FDG uptakes on PET/CT scans can accurately distinguish benign lesions from malignant lesions.
Acta Radiologica 01/2012; 53(3):249-54. · 1.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To determine whether [(18)F]FDG uptake on PET/CT imaging before surgical staging has prognostic significance in patients with epithelial ovarian cancer (EOC).
Patients with EOC were imaged with integrated PET/CT before surgical staging. Hypermetabolic lesions were measured as the standardized uptake value (SUV) in primary and metastatic tumors. SUV distribution was divided into two regions at the level of umbilicus, and the impact of the ratio between above and below umbilicus (SUV(location) ratio) on progression-free survival (PFS) was examined using Cox proportional hazards regression.
Between January 2004 and December 2009, 55 patients with EOC underwent preoperative PET/CT. The median duration of PFS was 11 months (range, 3 to 43 months), and twenty (36.4%) patients experienced recurrence. In univariate analysis, high SUV(location) ratio (p=0.002; hazard ratio [HR], 1.974; 95% confidence interval [CI], 1.286 to 3.031) was significantly associated with recurrence. Malignant mixed mullerian tumor compared with endometrioid histology was also shown to have significance. In multivariate analysis, high SUV(location) ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447) and histology (serous, mucinous, and malignant mixed mullerian tumor compared with endometrioid type) were significantly associated with recurrence. Patients were categorized into two groups according to SUV(location) ratio (<0.3934 vs. ≥0.3934), and the Kaplan-Meier survival graph showed a significant difference in PFS between the groups (p=0.0021; HR, 9.47, log-rank test).
SUV distribution showed a significant association with recurrence in patients with EOC, and may be a useful predictor of recurrence.
Journal of Gynecologic Oncology 01/2012; 23(1):28-34. · 1.49 Impact Factor
-
Jun Gyu Kim,
Min Jueng Kang,
Young-Kwang Yoon,
Hwang-Phill Kim,
Jinah Park,
Sang-Hyun Song,
Sae-Won Han,
Jong-Wan Park,
Gyeong Hoon Kang, Keon Wook Kang,
Do Youn Oh,
Seock-Ah Im,
Yung-Jue Bang,
Eugene C Yi,
Tae-You Kim
[show abstract]
[hide abstract]
ABSTRACT: Identification of predictive biomarkers is essential for the successful development of targeted therapy. Insulin-like growth factor 1 receptor (IGF1R) has been examined as a potential therapeutic target for various cancers. However, recent clinical trials showed that anti-IGF1R antibody and chemotherapy are not effective for treating lung cancer.
In order to define biomarkers for predicting successful IGF1R targeted therapy, we evaluated the anti-proliferation effect of figitumumab (CP-751,871), a humanized anti-IGF1R antibody, against nine gastric and eight hepatocellular cancer cell lines. Out of 17 cancer cell lines, figitumumab effectively inhibited the growth of three cell lines (SNU719, HepG2, and SNU368), decreased p-AKT and p-STAT3 levels, and induced G 1 arrest in a dose-dependent manner. Interestingly, these cells showed co-overexpression and altered mobility of the IGF1R and insulin receptor (IR). Immunoprecipitaion (IP) assays and ELISA confirmed the presence of IGF1R/IR heterodimeric receptors in figitumumab-sensitive cells. Treatment with figitumumab led to the dissociation of IGF1-dependent heterodimeric receptors and inhibited tumor growth with decreased levels of heterodimeric receptors in a mouse xenograft model. We next found that both IGF1R and IR were N-linked glyosylated in figitumumab-sensitive cells. In particular, mass spectrometry showed that IGF1R had N-linked glycans at N913 in three figitumumab-sensitive cell lines. We observed that an absence of N-linked glycosylation at N913 led to a lack of membranous localization of IGF1R and figitumumab insensitivity.
The data suggest that the level of N-linked glycosylated IGF1R/IR heterodimeric receptor is highly associated with sensitivity to anti-IGF1R antibody in cancer cells.
PLoS ONE 01/2012; 7(3):e33322. · 4.09 Impact Factor
-
Jun Sung Kim,
Young-Hwa Kim,
Jin Hyun Kim, Keon Wook Kang,
Eunju Lee Tae,
Hyewon Youn,
Daehong Kim,
Seok-Ki Kim,
Jung-Taek Kwon,
Myung-Haing Cho,
Yun-Sang Lee,
Jae Min Jeong,
June-Key Chung,
Dong Soo Lee
[show abstract]
[hide abstract]
ABSTRACT: To monitor cells in vivo or to detect the sentinel lymph node, we developed a PET/MRI silica nanoprobe with an enhanced near-infrared fluorescence signal.
We developed enhanced near-infrared fluorescent (NIRF) magnetic silica nanoparticles, MNP-SiO2(NIR797), that encapsulate NIRF dye in the silica. We applied this probe to visualizing cells in the deep tissue of mice using NIRF imaging. After labeling with a radioisotope, (68)Ga, on the surface of MNP-SiO2(NIR797), we injected it into the forepaw of mice to visualize the sentinel lymph node.
This encapsulated nanoprobe showed enhancement of fluorescent intensity and stability compared with the nanoprobe, which had the same dyes on the surface of the silica nanoparticles. We also obtained multimodal in vivo imaging of (68)Ga-{MNP-SiO2(NIR797)} applied to sentinel lymph node detection of mice using PET/MRI/NIRF images.
This multimodal nanoprobe with enhanced fluorescence may provide a useful tool for imaging diagnostics and cell tracking.
Nanomedicine 12/2011; 7(2):219-29. · 5.05 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: (68)Ga labeled NOTA-RGD was a recently developed positron emission tomography (PET) radiotracer for the visualization of angiogenesis, and is regarded as a promising imaging agent for cancer and several other disorders. In this study, we investigated the whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD in humans. Ten cancer patients (53.7 ± 13.5 years; 61.5 ± 7.4 kg) participated in this study. PET scans were performed using a PET/computed tomography (scanner in three-dimensional mode). After an intravenous injection of 172.4 ± 20.5 MBq of (68)Ga-NOTA-RGD, eight serial whole-body scans were performed during 90 minutes. Volumes of interest were drawn manually over the entire volumes of the urinary bladder, the gallbladder, heart, kidneys, liver, lungs, pancreas, spleen, and stomach. Time-activity curves were obtained from serial PET scan data. Residence times were calculated from areas under curve of time-activity curves and used as input to the OLINDA/EXM 1.1 software. The uptake of (68)Ga-NOTA-RGD was highest in the kidneys and urinary bladder. Radiation doses to kidneys and urinary bladder were 71.6 ± 28.4 μ Gy/MBq and 239.6 ± 56.6 μ Gy/MBq. Mean effective doses were 25.0 ± 4.4 μ Sv/MBq using International Commission of Radiation Protection (ICRP) publication 60 and 22.4 ± 3.8 μ Sv/MBq using ICRP publication 103 weighting factor. We evaluated the radiation dosimetry of (68)Ga labeled NOTA-RGD, which has an acceptable effective radiation dose.
Cancer Biotherapy & Radiopharmaceuticals 12/2011; 27(1):65-71. · 1.44 Impact Factor
